natgillin/translations-raw huggingface dataset:
Tell your doctor if you are taking or need to take ibuprofen (used to treat fever, inflammation and pain), amphotericin B (used to treat fungal infections), antibiotics (used to treat bacterial infections, e.g. aminoglycosides, vancomycin or clotrimazole) or antivirals (used to treat viral infections, e.g. aciclovir).
Obvestite zdravnika, če jemljete ali bi morali jemati ibuprofen (uporablja se za zdravljenje povišane telesne temperature, vnetja in bolečine), amfotericin B (uporablja se za zdravljenje glivičnih okužb),
abdominal pain, indigestion, constipation, passing wind, bloating, loose stools - bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver - itching, rash, hair loss, acne, increased sweating - pain in joints, limbs or back, muscle cramps - insufficient function of the kidneys, reduced production of urine, impaired or painful urination - general weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed - insufficient function of your transplanted organ
- srbenje, izpadanje las, akne, čezmerno znojenje - bolečine v sklepih, udih ali hrbtu, mišični krči - nezadostno delovanje ledvic, zmanjšano nastajanje seča, oslabljeno ali boleče uriniranje - splošna oslabelost, zvišana telesna temperatura, kopičenje tekočine v telesu, bolečine in nelagodje, zvišanje alkalne fosfataze v krvi, povečanje telesne mase, moteno zaznavanje telesne temperature - nezadostno delovanje presajenega organa
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels Clinically, the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or Hepatitis C Virus (HCV) protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib.
Močne interakcije so opazili z antimikotiki, kot so ketokonazol, flukonazol, itrakonazol, vorikonazol in izavukonazol, makrolidnim antibiotikom eritromicinom, zaviralci proteaz HIV (npr. ritonavir, nelfinavir, sakvinavir) ali zaviralci proteaze virusa hepatitisa C (HCV) (npr. telaprevir, bokeprevir in kombinacijo ombitasvirja in paritaprevirja z ritonavirjem, z dasabuvirjem ali brez njega), s farmakokinetičnim stopnjevalcem kobicistatom in zaviralcema tirozin-kinaze nilotinibom ter imatinibom.
Therapeutic drug monitoring of mycophenolic acid may be appropriate when switching from ciclosporin to tacrolimus or vice versa.
V primeru prehoda s ciklosporina na takrolimus ali obratno je lahko ustrezno terapevtsko spremljanje mikofenolne kisline.
Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.
V povezavi z zdravljenjem s takrolimusom so poročali o benignih in malignih neoplazmah, vključno z limfoproliferativnimi boleznimi, povezanimi z EBV in kožnimi malignomi.
Eye disorders, sometimes progressing to loss of vision, have been reported in patients treated with tacrolimus.
Pri bolnikih, zdravljenih s takrolimusom, so poročali o očesnih motnjah, ki so včasih napredovale do izgube vida.
Oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side.
Ovalna, bela do belkasta, neobložena tableta, z vtisom "0.75" na eni strani in "TCS" na drugi strani.
- medicines known as “statins”, used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy - prednisolone and methylprednisolone, belonging to the class of corticosteroids and used to treat inflammations or suppress the immune system (e.g. in transplant rejection) - carbamazepine, used to prevent and control seizures - metamizole, used to treat pain and high fever - nefazodone, used to treat depression - herbal preparations containing St. John's Wort (Hypericum perforatum)
- antiaritmiki (npr. amiodaron), ki se uporabljajo za obvladovanje aritmij (neenakomerno bitje srca) - zdravila, ki so znana kot "statini" in se uporabljajo pri zdravljenju zvišanega holesterola in trigliceridov - fenitoin ali fenobarbital, ki se uporabljata za zdravljenje epilepsije - prednizolon in metilprednizolon, ki spadata med kortikosteroide in se uporabljata za zdravljenje vnetij ali zaviranje imunskega sistema (npr. pri zavrnitvi presadka)
Tacrolimus blood trough levels should be determined approximately 24 hours post-dosing of Envarsus, just prior to the next dose.
Vzorce za določitev najmanjše koncentracije takrolimusa je treba vzeti približno 24 ur po uporabi zdravila
The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.
Kompleks FKBP12-takrolimus se specifično in kompetitivno veže na kalcinevrin in ga zavre.
Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking Envarsus.
Če ste po uporabi zdravila Envarsus omotični ali zaspani ali imate zamegljen vid, ne smete voziti vozil ali upravljati z orodji ali stroji.
Please contact your doctor immediately, should you experience severe effects.
Nemudoma obvestite zdravnika, če se vam med zdravljenjem pojavijo:
There is limited experience in non-Caucasian patients and patients at elevated immunological risk (e.g. retransplantation, evidence of panel reactive antibodies, PRA).
Pri bolnikih, ki niso bele rase in bolnikih z večjim imunološkim tveganjem (npr. retransplantacija,
Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload and oedema.
so obstoječa bolezen srca, jemanje kortikosteroidov, hipertenzija, moteno delovanje ledvic ali jeter, okužbe, preobremenitev s tekočino in edemi.
These may worsen kidney or nervous system problems when taken together with Envarsus.
Če se ta zdravila jemlje skupaj z zdravilom Envarsus, lahko poslabšajo težave z ledvicami ali živčevjem.
Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate).
Ena tableta s podaljšanim sproščanjem vsebuje 0,75 mg takrolimusa (v obliki monohidrata).
The efficacy failure rate as measured by the composite endpoint of death, graft loss, centrally read BPAR and loss to follow-up was 18.3% in the Envarsus group and 19.6% in the Prograf group.
centralno določena BPAR in bolnikov, izgubljenim za spremljanje, je bila 18,3 % za skupino z zdravilom Envarsus in 19,6 % za skupino z zdravilom Prograf.
Conversion of Prograf- or Advagraf-treated patients to Envarsus - allograft transplant patients Envarsus is not interchangeable with other existing tacrolimus containing medicinal products (immediate-release or prolonged-release) on an equal dose by dose basis.
Zdravilo Envarsus ni zamenljivo z drugimi obstoječimi zdravili, ki vsebujejo takrolimus (takojšnje sproščanje ali podaljšano sproščanje) na osnovi enakega odmerka.
Envarsus 0.75 mg prolonged-release tablets Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate).
KAKOVOSTNA IN KOLIČINSKA SESTAVA Envarsus 0,75 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 0,75 mg takrolimusa (v obliki monohidrata).
Only one of these has been shown in vitro to have immunosuppressive activity similar to that of tacrolimus.
da deluje podobno imunosupresivno kot takrolimus.
Envarsus 4 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “4” on one side and “TCS” on the other side.
Zdravilo Envarsus 4 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "4" na eni strani in "TCS" na drugi strani.
Envarsus 1 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side
Zdravilo Envarsus 1 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "1" na eni strani in "TCS" na drugi strani.
Investigations liver function tests abnormal blood alkaline phosphatase increased, weight increased amylase increased, ECG abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased echocardiogram abnormal,
povečanje telesne mase zvišanje amilaze, nepravilnosti na EKG, nenormalna srčna frekvenca in ritem, zmanjšanje telesne mase, zvišanje laktatdehidrogenaze v krvi ehokardiografske nepravilnosti
In clinical studies in kidney transplant patients receiving Envarsus, the most frequent adverse reactions (at least in 2% of patients) were tremor, diabetes mellitus, blood creatinine increased, urinary tract infection, hypertension, BK virus infection, renal impairment, diarrhoea, toxicity to various agents, and toxic nephropathy all of which are known to occur in the respective patient population under immunosuppressive treatment.
zvišanje kreatinina v krvi, okužbe sečil, hipertenzija, okužba z virusom BK, okvara ledvic, driska, toksičnost na različne učinkovine in toksična nefropatija, za katere je znano, da se pri imunosupresivnem zdravljenju pojavljajo pri zadevni populaciji bolnikov.
Envarsus contains lactose.
Zdravilo Envarsus vsebuje laktozo.
Vascular disorders hypertension thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders venous thrombosis deep limb, shock, infarction
žilne hipotenzivne motnje, krvavitev, bolezen perifernih žil globoka venska tromboza v udih, šok, infarkt
Common side effects (may affect up to 1 in 10 people): - reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests) - reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload,
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): - zmanjšanje števila krvnih celic (trombocitov in rdečih ali belih krvnih celic), povečanje števila belih krvnih celic, spremembe v številu rdečih krvnih celic (vidno na krvnih preiskavah)
Higher Cavg (~50%), reduced peak trough fluctuation (Cmax/Cmin) and a longer Tmax were seen for Envarsus when compared with both, tacrolimus immediate-release formulation (Prograf) and a tacrolimus once daily formulation (Advagraf).
(Cmax/Cmin) in daljši Tmax tako v primerjavi s takrolimusom s farmacevtsko obliko s takojšnjim sproščanjem (zdravilo Prograf) kot s takrolimusom s farmacevtsko obliko enkrat na dan (zdravilo
A negative effect of tacrolimus on male fertility in the form of reduced sperm count and motility was observed in rats.
Pri podganah so opažali negativen vpliv takrolimusa na moško plodnost; kazal se je z zmanjšanjem števila in gibljivosti semenčic.
Envarsus 0.75 mg prolonged-release tablets tacrolimus
Envarsus 0,75 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus 0.75 mg prolonged-release tablets
Envarsus 0,75 mg tablete s podaljšanim sproščanjem
Each prolonged-release tablet contains 4 mg tacrolimus (as monohydrate).
Ena tableta s podaljšanim sproščanjem vsebuje 4 mg takrolimusa (v obliki monohidrata).
Hepatobiliary disorders bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice venoocclusive liver disease, hepatic artery thrombosis hepatic failure
okvara jetrnih celic in hepatitis, holestaza in zlatenica venookluzivna bolezen jeter, tromboza jetrne arterije odpoved jeter
Envarsus 4 mg prolonged-release tablets Each prolonged-release tablet contains 4 mg tacrolimus (as monohydrate).
Envarsus 4 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 4 mg takrolimusa (v obliki monohidrata).
Uncommon side effects (may affect up to 1 in 100 people): - changes in blood clotting, reduction in the number of all types of blood cells (seen in blood tests) - dehydration, inability to urinate - psychotic behaviour, such as delusions, hallucinations, and confusion - abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase - coma, bleeding in the brain, stroke, paralysis, brain disorder, speech and language abnormalities, memory problems - clouding of the eye lens, partial or total inability to hear - irregular heartbeat, stop of heartbeat, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal - blood clot in a vein of a limb, shock - difficulties in breathing, respiratory tract disorders, asthma - acute or chronic inflammation of the pancreas, inflammation of the lining of the inner wall of the abdomen, obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach contents in your throat, delayed emptying of the stomach - inflammation of the skin, burning sensation in the sunlight - joint disorders - painful menstruation and abnormal menstrual bleeding - multiple organ failure, flu-like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, weight loss
- motnje strjevanja krvi, zmanjšanje števila vseh krvnih celic (vidno na krvnih preiskavah) - dehidracija, nezmožnost uriniranja - psihotično vedenje, kot so prividi, halucinacije in zmedenost - nenormalni rezultati krvnih preiskav: zmanjšanje beljakovin ali sladkorja v krvi, zvišanje fosfatov, zvišanje encima laktat-dehidrogenaze - koma, možganske krvavitve, možganska kap, paraliza, možganska motnja, motnje govora in izražanja, težave s spominom - motnost očesnih leč, delna ali popolna gluhost
Oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side.
Ovalna, bela do belkasta, neobložena tableta, z vtisom "1" na eni strani in "TCS" na drugi strani.
fever, nausea or vomiting - an infection, leading to problems with your kidney or neurological symptoms - headache, altered mental status, seizures and visual disturbances - weakness, change in skin or eye colour, easy bruising, infection, cough, anaemia
- glavobol, spremenjeno duševno stanje, krči in motnje vida, - oslabelost, sprememba barve kože ali oči, nagnjenost k podplutbam, okužba, kašelj, anemija.
Oval, white to off-white uncoated tablet, debossed with “4” on one side and “TCS” on the other side.
Ovalna, bela do belkasta, neobložena tableta, z vtisom "4" na eni strani in "TCS" na drugi strani.
Gastrointestinal perforation has been reported in patients treated with tacrolimus.
Pri bolnikih, zdravljenih s takrolimusom, so poročali o perforaciji prebavil.
Envarsus 1 mg prolonged-release tablets Each prolonged-release tablet contains 1 mg tacrolimus (as monohydrate).
Envarsus 1 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 1 mg takrolimusa (v obliki monohidrata).
Rare side effects (may affect up to 1 in 1,000 people): - Small bleedings in your skin due to blood clots - Increased muscle stiffness - Blindness, deafness
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): - mišična oslabelost
Very rare Not known
Neznani neželeni učinki (pogostnost ni znana):
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels Clinically, the following substances have been shown to decrease tacrolimus blood levels: Interactions have been observed with rifampicin, phenytoin, and St. John's Wort (Hypericum perforatum) which may require increased tacrolimus doses in almost all patients.
Induktorji CYP3A4, ki lahko povzročijo zmanjšane ravni takrolimusa v krvi Klinično je ugotovljeno, da koncentracijo takrolimusa v krvi zmanjšujejo naslednje snovi:
Envarsus 4 mg prolonged-release tablets
Envarsus 4 mg tablete s podaljšanim sproščanjem
Italy or
Italija ali
At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound.
(FKBP12), ki je odgovorna za njegovo znotrajcelično kopičenje.
- Collection of fluid around the heart - Acute breathlessness - Cyst formation in your pancreas, pre-stage of a blockage in your bowel - Problems with blood flow in the liver - Serious illness with blistering of skin, mouth, eyes and genitals; - Increased hairiness - Thirst, fall, feeling of tightness in your chest, decreased mobility, ulcer
- resno obolenje s pojavom mehurjev na koži, ustih, očeh in spolovilih - močnejša poraščenost - žeja, padci, občutek tiščanja v prsih, zmanjšana gibljivost, razjeda
- The need for specialist supervision and monitoring if there is a clinical decision to switch a patient to another tacrolimus containing products.
- Pri klinični odločitvi o prehodu bolnika na drugo zdravilo, ki vsebuje takrolimus, mora zdravljenje nadzirati in spremljati specialist.
Envarsus 1 mg prolonged-release tablets tacrolimus
Envarsus 1 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus 4 mg prolonged-release tablets tacrolimus
Envarsus 4 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus contains the active substance tacrolimus.
Zdravilo Envarsus vsebuje učinkovino takrolimus, ki je imunosupresiv.
Envarsus 1 mg prolonged-release tablets
Envarsus 1 mg tablete s podaljšanim sproščanjem
and combination tablets, used to treat HIV infection - HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir), used to treat hepatitis C - nilotinib and imatinib (used to treat certain cancers) - mycophenolic acid, used to suppress the immune system to prevent transplant rejection - medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine) - antiemetics, used to treat nausea and vomiting (e.g. metoclopramide) - cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn - the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol - medicines used to treat high blood pressure or heart problems (e.g. nifedipine, nicardipine,
- protiglivična zdravila in antibiotiki, zlasti t. i. makrolidni antibiotiki, ki se uporabljajo za zdravljenje okužb (npr. ketokonazol, flukonazol, itrakonazol, vorikonazol, klotrimazol in izavukonazol, eritromicin, klaritromicin, josamicin, izoniazid in rifampicin) - zaviralci proteaz HIV (npr. ritonavir, nelfinavir, sakvinavir), stopnjevalno zdravilo kobicistat in kombinirane tablete, ki se uporabljajo za zdravljenje okužbe z virusom HIV - zaviralci proteaze HCV (npr. telaprevir, bokeprevir in kombinacija ombitasvir/paritaprevir/ritonavir z dasabuvirjem ali brez njega), ki se uporabljajo za zdravljenje okužbe z virusom hepatitisa C - nilotinib in imatinib (ki se uporabljata za zdravljenje določenih vrst raka)
Renal and urinary disorders renal impairment renal failure, renal failure acute, nephropathy toxic, renal tubular necrosis, urinary abnormalities, oliguria, bladder and urethral symptoms haemolytic uraemic syndrome, anuria nephropathy , cystitis haemorrhag ic
nepravilnosti v sečilih, oligurija, simptomi sečnega mehurja in sečnice hemolitičnouremični sindrom, anurija nefropatija, hemora gični cistitis
Very common side effects (may affect more than 1 in 10 people): - increased blood sugar, diabetes mellitus, increased potassium in the blood - difficulty in sleeping - trembling, headache - increased blood pressure - liver function tests abnormal - diarrhoea, nausea - kidney problems
- povečanje vrednosti krvnega sladkorja, sladkorna bolezen, zvišanje vrednosti kalija v krvi - težave s spanjem - tresenje, glavobol
Other interactions potentially leading to increased tacrolimus blood levels Tacrolimus is extensively bound to plasma proteins.
Drugo medsebojno delovanje, ki lahko povzroči zvišane ravni takrolimusa v krvi
Envarsus is a once-a-day oral formulation of tacrolimus.
Zdravilo Envarsus je peroralna farmacevtska oblika takrolimusa, ki se ga jemlje enkrat na dan.
For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended, and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4).
Zato kombinirana uporaba ciklosporina in takrolimusa ni priporočljiva; pri bolnikih, ki so prej dobivali ciklosporin, je treba takrolimus uporabiti previdno
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS ALUMINIUM FOIL WRAPPER
OVOJNINAH OVITEK IZ ALUMINIJASTE FOLIJE
hallucination, mental disorders - fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders - blurred vision, increased sensitivity to light, eye disorders - ringing sound in your ears - reduced blood flow in the heart vessels, faster heartbeat - bleeding, partial or complete blocking of blood vessels, reduced blood pressure - shortness in breath, disorders of the respiratory tissues in the lung, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms - stomach problems such as inflammation or ulcer causing abdominal pain or diarrhoea, bleeding in the stomach, inflammation or ulcer in the mouth, collection of fluid in the belly, vomiting,
- sopenje, spremembe v pljučnem tkivu, nabiranje tekočine okrog pljuč, vnetje žrela, kašelj, gripi podobni simptomi - vnetja ali razjede s posledično bolečino v trebuhu ali drisko, krvavitve v želodcu, vnetje ali razjede v ustni votlini, nabiranje tekočine v trebušni votlini, bruhanje, bolečine v trebuhu, slaba prebava, zaprtje, vetrovi, napenjanje, mehko blato
Talk to your doctor before taking Envarsus: - if you have, or have had, liver problems.
Posvetujte se z zdravnikom, preden vzamete zdravilo Envarsus:
Unknown side effects (frequency not known): - Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), - Agranulocytosis (a severely lowered number of white blood cells) - Haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown) - Abnormality of the optic nerve (optic neuropathy)
- primeri čiste aplazije rdečih krvnih celic (zelo resno zmanjšanje števila rdečih krvnih celic)
Gastrointestinal disorders
Bolezni endokrinega sistema hirzutizem
Therefore, you should not breast-feed whilst taking Envarsus.
Med jemanjem zdravila Envarsus je treba zato prenehati z dojenjem.
Hypromellose
hemolitična anemija
Among the most frequent adverse reactions (at least in 2% of patients) in clinical studies in liver transplant patients receiving Envarsus were tremor, headache, fatigue, hyperkalaemia, hypertension, renal failure, blood creatinine increased, dizziness, hepatitis C, muscle spasms, tinea infection, leukopenia, sinusitis, and upper respiratory tract infections (URTI), all of which are known to occur in the respective patient population under immunosuppressive treatment.
hepatitis C, mišični spazmi, okužba s tineo, levkopenija, sinusitis in okužbe zgornjih dihal, za katere je znano, da se pri imunosupresivnem zdravljenju pojavljajo pri zadevni populaciji bolnikov.
Excipients
Advagraf).
Invented Name
EU številka Izmišljen o ime
These side effects were generally of mild or moderate severity.
Ti neželeni učinki so bili večinoma blagi ali zmerni.
The recommended dose is 1,500 mg, given either as a single infusion or as 1,000 mg in the first week followed by 500 mg one week later.
Priporočeni odmerek zdravila je 1 500 mg, ki se daje bodisi kot enkratna infuzija bodisi kot 1 000 mg infuzija v prvem tednu in 500 mg infuzija teden dni kasneje.